We are live on
!
Find out more
Crinetics Pharmaceuticals
CRNX
CRNX
243 hedge funds and large institutions have $4.46B invested in Crinetics Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 116 increasing their positions, 59 reducing their positions, and 40 closing their positions.
New
Increased
Maintained
Reduced
Closed
97% more repeat investments, than reductions
Existing positions increased: 116 | Existing positions reduced: 59
23% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 40
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
1% more funds holding
Funds holding: 240 → 243 (+3)
0.34% less ownership
Funds ownership: 117.6% → 117.26% (-0.34%)
14% less capital invested
Capital invested by funds: $5.19B → $4.46B (-$737M)
18% less call options, than puts
Call options by funds: $2.55M | Put options by funds: $3.1M
Holders
243
Holders Change
+3
Holders Change %
+1.25%
% of All Funds
2.99%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.07%
New
49
Increased
116
Reduced
59
Closed
40
Calls
$2.55M
Puts
$3.1M
Net Calls
-$549K
Net Calls Change
-$214K
Top Buyers
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$109M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$103M |
| 3 |
Jennison Associates
New York
|
-$16.8M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$15M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$10.9M |
